COMPANY

Immunomic Therapeutics, Inc.

HQ: Rockville, MD source · immunomix.com ↗

Also known as Immunomic Therapeutics · 7 sources

Immunomic Therapeutics develops nucleic acid vaccines from its investigational UNITE platform, which combines lysosomal targeting technology, adjuvants and antigen selection. Immunomic Therapeutics' pipeline focuses on immunotherapeutics for treating and preventing oncology indications. From company website Source · Source · checked 2026-10-19

Sources for this description (2)

Immunomic Therapeutics develops nucleic acid vaccines from its investigational UNITE platform, which combines lysosomal targeting technology, adjuvants and antigen selection.
- “Immunomic Therapeutics’ investigational UNITE ® platform is founded in a combination of complementary technologies and capabilities: ITI’s proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale.” https://immunomix.com/ (2026-10-19)
- “Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory.” https://immunomix.com/ (2026-10-19)
Immunomic Therapeutics' pipeline focuses on immunotherapeutics for treating and preventing oncology indications.
- “Stemming from our UNITE® Platform, Immunomic Therapeutics has developed a robust pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen.” https://immunomix.com/pipeline/ (2026-10-19)

Modality: nucleic acid vaccine

Therapeutic area: oncology

Keywords: vaccine Allergic Rhinoconjunctivitis Allergen Immunotherapy Triple Negative Breast Cancer Glioblastoma Merkel Cell Carcinoma Allergic Rhinitis ITI-9001 ITI-1001 ITI-3000

Location: Rockville, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

Jul 14, 2026 Trial start 1: Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer source ↗
Jun 20, 2026 Trial start 1: Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Ceda source ↗
Aug 21, 2023 Trial start Phase 1: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) source ↗
Jun 13, 2022 Trial start Phase 1: Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) source ↗
2014-06 Trial start IC: A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device source ↗
2013-09 Trial start IB: A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects source ↗
2012-10 Trial start I: A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid source ↗

Upcoming milestones

2028-02 (ESTIMATED) · 1 · Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar ( · NCT07726147
2028-02 (ESTIMATED) · 1 · Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer · NCT07652242

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07726147	Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis	1	Recruiting	Jun 20, 2026	2028-02 (estimated)
NCT07652242	Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer	1	Recruiting	Jul 14, 2026	2028-02 (estimated)
NCT05698199	Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)	Phase 1	Completed	Aug 21, 2023	Feb 11, 2026 (actual)
NCT05422781	Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)	Phase 1	Completed	Jun 13, 2022	Jun 27, 2023 (actual)
NCT02146781	A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device	IC	Completed	2014-06	2015-03 (actual)
NCT01707069	A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid	I	Completed	2012-10	2013-05 (actual)
NCT01966224	A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects	IB	Completed	2013-09	2013-12 (actual)